Lexaria Bioscience (LEXX) Return on Sales [ROS] (2017 - 2026)
Lexaria Bioscience's Return on Sales [ROS] was -3973.16% in fiscal Q3 2026 (quarter ended May 31, 2026), down 1817.75 percentage points from -2155.41% a year earlier but up 3286.35 percentage points from the prior quarter.
Powered by 
Analysis
Lexaria Bioscience (LEXX) Return on Sales [ROS] (2017 - 2026) Analysis & Trends
For FY2025 (ended Aug 31, 2025), Return on Sales [ROS] at Lexaria Bioscience came in at -1683.01%, down 443.85 percentage points from FY2024.
- Return on Sales [ROS] shows a five-year change of -365.06 percentage points (FY2020 to FY2025).
- In earlier fiscal years, Return on Sales [ROS] was -1239.16% in FY2024 (+1649.35 pp), -2888.50% in FY2023 (-296.84 pp), -2591.67% in FY2022 (-1804.82 pp) and -786.85% in FY2021 (+531.10 pp).
- Quarterly Return on Sales [ROS] has moved between -14434.31% (fiscal Q1 2022) and -460.69% (fiscal Q2 2024) over five years.
- Compared with a year earlier, Return on Sales [ROS] has declined for three straight quarters, with an average year-over-year change of -990.88 percentage points over the last eight quarters.
- The best year-over-year quarter for Return on Sales [ROS] over five years was fiscal Q1 2023 (a gain of 12699.60 percentage points); the worst was fiscal Q1 2022 (a drop of 14193.11 percentage points).
- Per Business Quant data, LEXX's Return on Sales [ROS] in the three fiscal quarters before Q3 2026 was -7259.52% (Q2 2026), -2062.00% (Q1 2026) and -1545.17% (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 51.16% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 28.21% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 37.86% |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -3.52% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 32.97% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 20.57% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 34.95% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -133.21% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 28.37% |
| 10 | Lexaria Bioscience | 3.04 Mn | -12.61 Mn | - | -3,973.16% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2026 | -3,973.16% |
| Feb 28, 2026 | -7,259.52% |
| Nov 30, 2025 | -2,062.00% |
| Aug 31, 2025 | -1,545.17% |
| May 31, 2025 | -2,155.41% |
| Feb 28, 2025 | -1,581.04% |
| Nov 30, 2024 | -1,462.95% |
| Aug 31, 2024 | -2,622.70% |
| May 31, 2024 | -2,074.90% |
| Feb 29, 2024 | -460.69% |
| Nov 30, 2023 | -753.01% |
| Aug 31, 2023 | -3,624.19% |
| May 31, 2023 | -3,089.64% |
| Feb 28, 2023 | -6,609.86% |
| Nov 30, 2022 | -1,734.71% |
| Aug 31, 2022 | -673.46% |
| May 31, 2022 | -2,425.20% |
| Feb 28, 2022 | -4,726.50% |
| Nov 30, 2021 | -14,434.31% |
| Aug 31, 2021 | -4,199.30% |
API Access
Lexaria Bioscience Return on Sales [ROS] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=LEXX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-sales-[ros]", "ticker": "LEXX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=LEXX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();